Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06562582

STunning in Acute Myocardial Infarction - BAS

The objective of this trial is to examine the effect of immediate versus late administration of beta blockers, angiotensin converting enzyme inhibitors (ACEI), and sodium/glucose cotransporter 2 (SGLT2) inhibitors on echocardiographic parameters and biomarkers in subjects with ST-elevation myocardial infarction (STEMI)

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Sahlgrenska University Hospital

Gothenburg, 41345, Sweden

Location status: Recruiting

About this study

Left ventricular (LV) remodeling after ST-elevation myocardial infarction (STEMI) is associated with poor outcomes, but the mechanisms underlying adverse LV remodeling are poorly understood. It is also poorly understood how current guideline-recommended treatments affect early LV remodeling. This low interventional clinical trial will compare the effects of early versus late initiation of the three pharmacotherapies on early LV remodeling and cardiometabolic profiles.

Trial objective:

The objective of this trial is to examine the effect of immediate versus late administration of beta blockers, angiotensin converting enzyme inhibitors (ACEI), and sodium/glucose cotransporter 2 (SGLT2) inhibitors on echocardiographic parameters and biomarkers in subjects with ST-elevation myocardial infarction (STEMI).

Primary endpoint:

Global longitudinal strain (GLS, %) at day 7±24 hours after PCI, adjusted for baseline (day 0) GLS.

Trial design:

This prospective, 2x2x2 factorial, randomized, controlled, open-label, low intervention clinical trial will enroll subjects with STEMI who undergo primary percutaneous coronary intervention (PCI) within 6 hours of symptom onset.

Trial population:

Patients over the age of 18 with STEMI who undergo primary PCI

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with STEMI who undergo primary PCI within 6 hours of symptom onset (Excluding prodromal symptoms)
  • Informed consent

Exclusion criteria

  • Killip class ≥ 3
  • Chronic kidney disease with GFR < 25 ml/min/1.73 m2
  • Pre-existing non-reversible cardiac dysfunction or heart failure
  • Current treatment with any beta blocker, RAAS inhibitor or SGLT2 inhibitor
  • Absolute or relative contraindication to any one of the study drugs that confers a risk of patient safety if the patient participates in the trial and adheres to the protocol-specified recommendations, per the assessment of the treating physician
  • Life expectancy less than one year
  • Pregnancy or women of childbearing potential who is not sterilized or is not using a medically accepted form of contraception

Treatment and study plan

Bisoprolol Oral Tablet

Drug

Timing of drug intervention after PCI

Other names: Betablocker

Ramipril Oral Product

Drug

Timing of drug intervention after PCI

Other names: ACE inhibitor

Dapagliflozin Oral Product

Drug

Timing of drug intervention after PCI

Other names: SGLT2 inhibitor

Primary outcomes

  1. Measurement of Global longitudinal strain (GLS, %)

    Time frame: day 7±24 hours

    GLS adjusted for baseline.

Secondary outcomes

  1. Measurement of Left ventricular ejection fraction (LVEF)

    Time frame: day 7±24 hours

    LVEF adjusted for baseline

  2. Measurement of NT-proBNP (N-terminal pro b-type natriuretic peptide )

    Time frame: day 7±24 hours

    NT-proBNP adjusted for baseline

  3. Concentration of cardiac troponin-T

    Time frame: Day 30

    Area under the curve

  4. Concentration of cardiac troponin-I

    Time frame: Day 30

    Area under the curve

Other outcomes

  1. Measurement of Infarct size

    Time frame: Day 30

    MI size assessed by CMRI (sub-study)

Study contacts

Contact information is provided by the study sponsor or research team.

Björn Redfors, Professor

CONTACT

[email protected]

+46 31342100

Margareta Scharin Täng, PhD

CONTACT

[email protected]

0736916467

Sponsors and collaborators

Lead sponsor

Vastra Gotaland Region

Other Gov

Registry information

Official study title

STunning in Acute Myocardial Infarction - Beta Blockers, Angiotensin Converting Enzyme Inhibitors and Sodium/Glucose Cotransporter 2 Inhibitors Trial A Low Intervention Clinical Tria

Acronym: STAMI-BAS

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Aug 20, 2024
Registry last updated
Jun 27, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.